Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 88 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

7%

6 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

45Total
Not Applicable (25)
Early P 1 (1)
P 1 (6)
P 2 (7)
P 4 (6)

Trial Status

Recruiting45
Not Yet Recruiting22
Completed12
Enrolling By Invitation6
Suspended1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 12 completed trials

Clinical Trials (88)

Showing 20 of 20 trials
NCT07077746Phase 2RecruitingPrimary

HB-adMSCs for the Treatment of Crohn's Disease

NCT07686757Phase 4Not Yet Recruiting

INSIGHT-IBD Pragmatic Study

NCT06773182Not ApplicableCompleted

Assessing Interventions of Diet in IBD

NCT07471438Not ApplicableRecruitingPrimary

Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease.

NCT07316621RecruitingPrimary

Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives

NCT07719426Not Yet RecruitingPrimary

Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study

NCT07170462Early Phase 1RecruitingPrimary

Cranberry and Gut Health in Crohn's Disease

NCT07224113Recruiting

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

NCT07694674Recruiting

Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease

NCT07245394Recruiting

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07686406RecruitingPrimary

IBD Biomarker Discovery and Validation Platform

NCT07616687Phase 4RecruitingPrimary

Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

NCT07508592Not ApplicableCompleted

Feasibility Study of the SEGER Device in Laparoscopic Gastrointestinal Surgery

NCT07647640Not Yet Recruiting

Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device Study

NCT07656233Not ApplicableCompleted

Effect of Isoflavone and Vitamin D Supplementation on Serum Vitamin D Levels, Body Composition, Inflammatory Markers, and Quality of Life in Patients With Inflammatory Bowel Disease

NCT07652632Not ApplicableRecruitingPrimary

Regenerative Endoscopy in Refractory Perianal Crohn's Disease

NCT07649408RecruitingPrimary

Impact of Advanced Crohn's Disease Therapies on Sleep Quality

NCT07644117Recruiting

Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease

NCT07625293Phase 2Not Yet RecruitingPrimary

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

NCT07644390CompletedPrimary

Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal Surgery Using Longitudinal Indices of Routine Blood Tests: A Single-Center Retrospective Cohort Study

Scroll to load more

Research Network

Activity Timeline